These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 32213029)

  • 21. Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development.
    Nelson SR; Zhang C; Roche S; O'Neill F; Swan N; Luo Y; Larkin A; Crown J; Walsh N
    Sci Rep; 2020 Feb; 10(1):2778. PubMed ID: 32066753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week.
    Hu Y; Sui X; Song F; Li Y; Li K; Chen Z; Yang F; Chen X; Zhang Y; Wang X; Liu Q; Li C; Zou B; Chen X; Wang J; Liu P
    Nat Commun; 2021 May; 12(1):2581. PubMed ID: 33972544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.
    Hennig A; Baenke F; Klimova A; Drukewitz S; Jahnke B; Brückmann S; Secci R; Winter C; Schmäche T; Seidlitz T; Bereuter JP; Polster H; Eckhardt L; Schneider SA; Brückner S; Schmelz R; Babatz J; Kahlert C; Distler M; Hampe J; Reichert M; Zeißig S; Folprecht G; Weitz J; Aust D; Welsch T; Stange DE
    J Pathol; 2022 Aug; 257(5):607-619. PubMed ID: 35373359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
    Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
    Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
    Burkhart RA; Baker LA; Tiriac H
    Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids.
    Palzer J; Mues B; Goerg R; Aberle M; Rensen SS; Olde Damink SWM; Vaes RDW; Cramer T; Schmitz-Rode T; Neumann UP; Slabu I; Roeth AA
    Int J Nanomedicine; 2021; 16():2965-2981. PubMed ID: 33935496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
    Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
    Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer.
    Zhao Y; Li S; Zhu L; Huang M; Xie Y; Song X; Chen Z; Lau HC; Sung JJ; Xu L; Yu J; Li X
    Cell Rep Med; 2024 Jul; 5(7):101627. PubMed ID: 38964315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
    Schuth S; Le Blanc S; Krieger TG; Jabs J; Schenk M; Giese NA; Büchler MW; Eils R; Conrad C; Strobel O
    J Exp Clin Cancer Res; 2022 Oct; 41(1):312. PubMed ID: 36273171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Organoid models for translational pancreatic cancer research.
    Tiriac H; Plenker D; Baker LA; Tuveson DA
    Curr Opin Genet Dev; 2019 Feb; 54():7-11. PubMed ID: 30844513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
    Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
    Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applications of patient-derived tumor xenograft models and tumor organoids.
    Yoshida GJ
    J Hematol Oncol; 2020 Jan; 13(1):4. PubMed ID: 31910904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Organoid models of human and mouse ductal pancreatic cancer.
    Boj SF; Hwang CI; Baker LA; Chio II; Engle DD; Corbo V; Jager M; Ponz-Sarvise M; Tiriac H; Spector MS; Gracanin A; Oni T; Yu KH; van Boxtel R; Huch M; Rivera KD; Wilson JP; Feigin ME; Öhlund D; Handly-Santana A; Ardito-Abraham CM; Ludwig M; Elyada E; Alagesan B; Biffi G; Yordanov GN; Delcuze B; Creighton B; Wright K; Park Y; Morsink FH; Molenaar IQ; Borel Rinkes IH; Cuppen E; Hao Y; Jin Y; Nijman IJ; Iacobuzio-Donahue C; Leach SD; Pappin DJ; Hammell M; Klimstra DS; Basturk O; Hruban RH; Offerhaus GJ; Vries RG; Clevers H; Tuveson DA
    Cell; 2015 Jan; 160(1-2):324-38. PubMed ID: 25557080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer.
    Seppälä TT; Zimmerman JW; Sereni E; Plenker D; Suri R; Rozich N; Blair A; Thomas DL; Teinor J; Javed A; Patel H; Cameron JL; Burns WR; He J; Tuveson DA; Jaffee EM; Eshleman J; Szabolcs A; Ryan DP; Ting DT; Wolfgang CL; Burkhart RA
    Ann Surg; 2020 Sep; 272(3):427-435. PubMed ID: 32657929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
    Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
    Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
    Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
    Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models.
    Tiriac H; French R; Lowy AM
    J Vis Exp; 2020 Jan; (155):. PubMed ID: 32009658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optical Imaging of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals Heterogeneous Drug Response.
    Walsh AJ; Castellanos JA; Nagathihalli NS; Merchant NB; Skala MC
    Pancreas; 2016 Jul; 45(6):863-9. PubMed ID: 26495796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
    Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.